[{"address1": "480 Pleasant Street", "address2": "Suite A-210", "city": "Watertown", "state": "MA", "zip": "02472", "country": "United States", "phone": "617 926 5000", "fax": "617 926 5050", "website": "https://eyepointpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.", "fullTimeEmployees": 165, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jay S. Duker M.D.", "age": 65, "title": "President, CEO & Director", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 1193809, "exercisedValue": 0, "unexercisedValue": 256720}, {"maxAge": 1, "name": "Dr. Ramiro  Ribeiro M.D., Ph.D.", "age": 41, "title": "Chief Medical Officer", "yearBorn": 1983, "fiscalYear": 2024, "totalPay": 742578, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marcia  Sellos-Moura Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ron I. Honig Esq.", "title": "Chief Legal Officer & Company Secretary", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer  Leonard", "title": "Chief People Officer & Senior VP of  IT", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David Scott Jones M.A.", "age": 57, "title": "Senior VP & Chief Commercial Officer", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 672084, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Isabelle  Lefebvre", "title": "Chief Regulatory Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael J. Maciocio", "title": "Chief Manufacturing Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Anna  Kluczewska", "title": "CEO of AION Diagnostics Ltd, President of AION Diagnostics Ltd and Director of AION Diagnostics Ltd", "fiscalYear": 2024, "totalPay": 169830, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 4, "compensationRisk": 7, "shareHolderRightsRisk": 4, "overallRisk": 5, "governanceEpochDate": 1756684800, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 13.33, "open": 13.31, "dayLow": 13.205, "dayHigh": 13.58, "regularMarketPreviousClose": 13.33, "regularMarketOpen": 13.31, "regularMarketDayLow": 13.205, "regularMarketDayHigh": 13.58, "payoutRatio": 0.0, "beta": 1.952, "forwardPE": -4.7173147, "volume": 633188, "regularMarketVolume": 633188, "averageVolume": 740703, "averageVolume10days": 914280, "averageDailyVolume10Day": 914280, "bid": 9.66, "ask": 17.1, "bidSize": 2, "askSize": 2, "marketCap": 920180800, "fiftyTwoWeekLow": 3.91, "fiftyTwoWeekHigh": 14.42, "priceToSalesTrailing12Months": 17.730564, "fiftyDayAverage": 11.0738, "twoHundredDayAverage": 8.1529, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 688163136, "profitMargins": 0.0, "floatShares": 42619895, "sharesOutstanding": 68927400, "sharesShort": 8450737, "sharesShortPriorMonth": 6910406, "sharesShortPreviousMonthDate": 1753920000, "dateShortInterest": 1756425600, "sharesPercentSharesOut": 0.122600004, "heldPercentInsiders": 0.03514, "heldPercentInstitutions": 1.01328, "shortRatio": 12.78, "shortPercentOfFloat": 0.147, "impliedSharesOutstanding": 68927400, "bookValue": 3.571, "priceToBook": 3.7384486, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -175380992, "trailingEps": -2.69, "forwardEps": -2.83, "lastSplitFactor": "1:10", "lastSplitDate": 1607472000, "enterpriseToRevenue": 13.26, "enterpriseToEbitda": -3.677, "52WeekChange": 0.51018095, "SandP52WeekChange": 0.16885936, "quoteType": "EQUITY", "currentPrice": 13.35, "targetHighPrice": 68.0, "targetLowPrice": 23.0, "targetMeanPrice": 34.41667, "targetMedianPrice": 29.5, "recommendationMean": 1.30769, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 12, "totalCash": 255732992, "totalCashPerShare": 3.71, "ebitda": -187140992, "totalDebt": 23715000, "quickRatio": 7.727, "currentRatio": 7.996, "totalRevenue": 51898000, "debtToEquity": 9.64, "revenuePerShare": 0.802, "returnOnAssets": -0.37785998, "returnOnEquity": -0.73950994, "grossProfits": -133707000, "freeCashflow": -114199624, "operatingCashflow": -190586000, "revenueGrowth": -0.437, "grossMargins": -2.57634, "ebitdaMargins": 0.0, "operatingMargins": -11.66829, "financialCurrency": "USD", "symbol": "EYPT", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "EyePoint Pharmaceuticals, Inc.", "longName": "EyePoint Pharmaceuticals, Inc.", "marketState": "CLOSED", "fiftyDayAverageChange": 2.2762003, "fiftyDayAverageChangePercent": 0.20554826, "twoHundredDayAverageChange": 5.1971006, "twoHundredDayAverageChangePercent": 0.6374543, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1757715867, "regularMarketTime": 1757707201, "exchange": "NGM", "messageBoardId": "finmb_4481199", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 0.150041, "regularMarketPrice": 13.35, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1106836200000, "postMarketChangePercent": -1.1236, "postMarketPrice": 13.2, "postMarketChange": -0.150001, "regularMarketChange": 0.0200005, "regularMarketDayRange": "13.205 - 13.58", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 740703, "fiftyTwoWeekLowChange": 9.440001, "fiftyTwoWeekLowChangePercent": 2.4143224, "fiftyTwoWeekRange": "3.91 - 14.42", "fiftyTwoWeekHighChange": -1.0699997, "fiftyTwoWeekHighChangePercent": -0.07420248, "fiftyTwoWeekChangePercent": 51.018097, "dividendDate": 1607472000, "earningsTimestamp": 1754483400, "earningsTimestampStart": 1762345800, "earningsTimestampEnd": 1762345800, "earningsCallTimestampStart": 1754483400, "earningsCallTimestampEnd": 1754483400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -2.69, "epsForward": -2.83, "epsCurrentYear": -3.02714, "priceEpsCurrentYear": -4.4101033, "displayName": "EyePoint Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-09-13"}]